Полифармацевтика, сопутствующие факторы и изменения с течением времени в австралийцах с множественным склерозом.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Ting, Ahmad Hasnat, Ng Huah Shin, Laslett Laura, van der Mei Ingrid, Taylor Bruce, Palmer Andrew J
Аннотация
Оригинал публикации
Polypharmacy prevalence, associated factors, and changes over time in Australians with multiple sclerosis.
BACKGROUND: People with multiple sclerosis (PwMS) face a high risk of polypharmacy due to symptom management and comorbidities, yet research remains limited.
OBJECTIVES: To examine polypharmacy prevalence, associated factors, and temporal trends among Australians with MS.
METHODS: Data were drawn from the Australian Multiple Sclerosis Longitudinal Study. Prescription records were obtained from Pharmaceutical Benefits Scheme (PBS) datasets (2017-2022). Polypharmacy was defined as the use of ≥5 medications prescribed at least four times a year. Prevalence of overall, low-to-moderate (5-9 medications) and hyper-polypharmacy (≥10 medications) was calculated for 2022. Log-binomial regression was used to identify factors associated with polypharmacy. Among those having PBS data for every year of 2017-2022, the average annual percentage change in polypharmacy prevalence was estimated using Poisson regression.
RESULTS: In 2022, 24 % of PwMS experienced polypharmacy (22 % low-to-moderate; 3 % hyper-polypharmacy). Higher age, disability, number of comorbidities, and lower education were associated with higher likelihood of polypharmacy. Common self-reported comorbidities associated with higher polypharmacy prevalence included type 2 diabetes (prevalence ratio [95 % confidence interval]: 2.03 [1.61-2.56]), hypertension (1.49 [1.19-1.85]), high cholesterol (1.41 [1.14-1.75]), and depression (1.35 [1.07-1.71]). Polypharmacy prevalence increased consistently, with an average annual rate of 4.51 %.
CONCLUSION: Polypharmacy is common and increasing among PwMS. Older PwMS with higher disability levels, more comorbidities and lower levels of education are more likely to benefit from a formal review of their medications.